Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Hodgkin Disease

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Hodgkin Lymphoma

Patients receiving autologous TAA-specific cytotoxic CTLs

Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:

2 x 10\^7/m2

TAA-specific CTLs

Lauren Scherer, MD

Wendy Callejas

Investigators have previously used this sort of therapy to treat Hodgkin or non-Hodgkin lymphoma that is associated with the virus that causes infectious mononucleosis ("mono" or the "kissing disease"), Epstein-Barr virus (EBV). EBV is found in cancer cells of up to half of all patients with Hodgkin's and non-Hodgkin lymphoma. This suggests that it may play a role in causing lymphoma. The cancer cells infected by EBV are able to hide from the body's immune system and escape being killed. Investigators previously tested special white blood cells (cells that help the body fight disease and infection), called T cells. The T cells were trained to kill EBV-infected cells and were tested to see whether treatment with these cells could affect these tumors. In many patients investigators found that giving these trained T cells caused a complete or partial response.

However, many patients do not have EBV found in their lymphoma cells. Therefore, investigators now want to test whether special T lymphocytes directed against other types of proteins that show on the tumor cell surface can result in similar promising results. The proteins that will be targeted in this study are called tumor-associated antigens (TAAs) - these are cell proteins that are specific to the cancer cell, so they either do not show or show up in low quantities on normal human cells.

In this stage of the study, investigators will target five TAAs which commonly show on lymphoma cells , called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. Investigators will do this by using special types of T cells called cytotoxic T lymphocytes (CTLs) generated in the lab. These TM-specific T cells are an investigational product not yet approved by the U.S. Food and Drug Administration.

The purpose of this stage of the study is to find out if TM-specific cytotoxic T cells are safe in children. The investigators want to learn what the side-effects are, and to see whether this therapy might help treat patients who are considered high risk for relapse of Hodgkin disease or non-Hodgkin lymphoma.

First, patients provide blood for us to make TAA-specific cytotoxic T cells in the lab. The amount of blood to be drawn will be less based on the child's weight per blood draw (3 mL/kg). Under certain conditions related to the patient's health, investigators may need to collect the blood using a process called apheresis. Apheresis is the process where blood is passed through a machine that separates out the components of the patient's blood that is needed. The remainder of the patient's blood is then returned to the patient's body.

If the TAA-specific cytotoxic T cells can be made, the time from collection of the blood to manufacture of T cells for administration to the patient is about 1 to 2 months.

The cells will then be injected by IV into the patient over 10 minutes. The patient may be pre-treated with acetaminophen (Tylenol) and diphenhydramine (Benadryl). Acetaminophen (Tylenol) and diphenhydramine (Benadryl) are given to prevent a possible allergic reaction to the T cell administration. Initially, two doses of T cells will be given two weeks apart. The patient's lymphoma will be assessed before the infusion (pre-infusion) and then 6 weeks after the second infusion. If after the patient's second infusion he/she has not relapsed or experienced a side effect which would prevent him/her from receiving any more cells, he/she can receive up to six (6) additional doses if they wish. The T cells would then be given at 6-8 week intervals.

In between the first and second T cell infusions and for 6 weeks after the last infusion, investigators ask that the patient not receive any other anti-cancer treatments such as radiation therapy or chemotherapy. If the patient does receive any other therapies in-between the first and second infusion of T cells, they will be taken off treatment and will not be able to receive the second infusion of T cells. All of the treatments will be given by the Center for Cell and Gene Therapy at Texas Children 's Hospital.

MEDICAL TESTS BEFORE TREATMENT

Before being treated,the patient will receive a series of standard medical tests:

* Physical exam.
* Blood tests to measure blood cells, kidney and liver function.
* Measurements by routine imaging studies to confirm the patient is in remission. Investigators will use the imaging study that was used before to follow the patient's tumor: CT, MRI, or PET.
* Pregnancy test if the patient is a female who can have children.

MEDICAL TESTS AFTER TREATMENT

- Imaging study 8 weeks after the 2nd TAA-CTL infusion.

To learn more about the way the T cells are working in the patient's body , an extra 20-40 ml (4-8 teaspoons) of blood or 3ml/kg of body weight of blood (whichever is less) will be taken before the infusion, and at weeks 2, 4 and 8. Afterwards, blood will be collected at 3, 6, 9 and 12 months after the last infusion. The blood may be drawn from the patient's central line at the time of his or her regular blood tests. Investigators will use this blood to see how long the T cells last, and to look at the patient's immune response to their cancer.

If the patient receives additional doses of T cells this blood will also be collected before each infusion and 1, 2, 4, and 6 weeks post each infusion.

The maximum amount of blood that may be drawn over the course of the study is 156 to 312 teaspoon.

Investigators may request a sample of a previous tumor biopsy the patient has had or from a tumor biopsy performed at any time while the patient is on this study. The sample will be used for research purposes related to this study.

In the event of death, investigators will request permission to perform an autopsy to learn more about the effects of the treatment on the patient's disease.

STUDY DURATION The patient's active participation in this study will last for approximately one 1 year. If they receive additional doses of the T cells as described above, their active participation will last until one 1 year after their last dose of T cells. Investigators will then contact them once a year for up to 4 additional years (total of 5 years follow-up) in order to evaluate their disease response long-term.

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL)

Treatment-related adverse event (tAE) rate is the proportion of participants with tAE measured by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The tAE will be defined as development of Grade III-IV events in any organ system that do not return to grade I within 72 hours with the exception of events that are clearly unrelated, and, of hematological toxicities, which are only considered a tAE if Grade III persisting for up to 10 days or greater than or equal to Grade IV. In addition grade 2 or greater autoimmune reaction will be considered a tAE.

Information on the expansion, persistence and anti-tumor effects of the adoptively transferred tumor-specific CTL will be analyzed for the immunological parameters based on multimer analysis, intracellular cytokine staining and ELIspot assays to assess the frequency of cells secreting γ-IFN using the descriptive statistics such as mean, median, standard deviation at each time point. Comparison of diagnostic imaging studies from pre-infusion to 6 weeks following the second infusion will be summarized

Center for Cell and Gene Therapy, Baylor College of Medicine

Baylor College of Medicine

Clinical Instructor

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Gland and Hormone Related Diseases

Uterine Cervical Neoplasms

Carcinoma

Adenocarcinoma

Melanoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Ovarian Cancer

Ovarian Epithelial Cancer

Dermatologic Agents

All Drugs and Chemicals

Coal Tar

HLA genotyping and tumor tissue profiling for certain TAA and LOH.

Tumor and HLA Profiling

Marlyane Motta, BS

OncoBay Clinical CRO

Justin Moser, MD

Jialing Zhang

Michael Hurwitz, MD

Brian Pico, MD

Marialby Donis Ramos

Jose Lutzky, MD

Melinda Porter

Sajeve Thomas, MD

Ben Orem

Jaspreet Grewal, MD

Marie Ventimiglia

Ira Winer, MD

Manar Al-Assi

Elizabeth Shelton, MPH

Brian Henick, MD

UNC Immunotherapy Team

Jared Weiss, MD

Cancer Answer Line

James Isaacs, MD

Rom Leidner, MD

Shelly Evans

Yazan Samhouri, MD

Barb Stadterman

Jason Luke, MD

Dawn Pinchasik, MD

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if subjects meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical treatment study.

This multicenter screening study will be conducted to determine a subject's tumor antigen expression profile, HLA genotype and HLA LOH for TScan sponsored clinical treatment study(s). No treatment intervention will occur as part of this screening study.

Subjects will be required to provide a buccal swab to assess their HLA status. If they are positive for certain types of HLA, subjects will provide a saliva sample to assess HLA loss of heterozygosity. In parallel, archival tissue (less than 8 months old) will be needed to assess for tumor antigen expression. If archival tissue is older than 8 months, a fresh tumor biopsy will be required at the time of the second visit.

If eligible, subjects will be referred to appropriate available interventional trial(s) at the discretion of the Investigator.

Diagnostic Test: Tumor Profiling for TAA expression, HLA typing and HLA loss.

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors

To identify subjects with Head and Neck, Cervical, Ovarian, Melanoma, Non-Small Cell Lung HPV positive anogenital and other types of cancers that could potentially be eligible for the TScan Therapeutics clinical trials.

TScan Therapeutics, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).	NCT05134740	Hodgkins Lympho... Non Hodgkins Ly...	TAA-specific CT...	1 Year - 21 Years	Baylor College of Medicine
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors	NCT05812027	Head and Neck C... Cervical Cancer Non Small Cell ... Melanoma Ovarian Cancer HPV16 Related C...	Tumor and HLA P...	18 Years -	TScan Therapeutics, Inc.
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).	NCT05134740	Hodgkins Lympho... Non Hodgkins Ly...	TAA-specific CT...	1 Year - 21 Years	Baylor College of Medicine
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors	NCT05812027	Head and Neck C... Cervical Cancer Non Small Cell ... Melanoma Ovarian Cancer HPV16 Related C...	Tumor and HLA P...	18 Years -	TScan Therapeutics, Inc.

Spots Global Cancer Trial Database for taa

Every month we try and update this database with for taa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for taa

Every month we try and update this database with for taa cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for taa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.